PD1 Inhibitors & Immunotherapy in Cancer Care

Jeff Infante, M.D.

PD1 Inhibitors & Immunotherapy in Cancer Care

Dr. Jeff Infante, of Tennessee Oncology and the Director of the Drug Development Unit at the Sarah Cannon Research Institute, discusses recent clinical trials involving immunotherapy, specifically the PD1 inhibitor pathway. Immunotherapy studies observe the interactions between the immune system and cancer cells and finds ways to block the immune system’s tolerance of cancers.